Evaluación positiva de medicamentos: marzo y abril 2018 Sanid. mil. 2018 74 (3) 167 riority SWORD-1 and SWORD-2 studies. Lancet 2018; 391(10123): 839-49. 11. Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M, et al. Effectiveness, Safe-ty, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients. Ann Pharmacother. 2018; 52(1):11-8. 12. Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplifi-cation strategy: a cohort study. HIV Med. 2017; 18 (9):704-708. 13. EMA. EPAR – Public assessment report for Zessly®. Disponible en: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_as-sessment_ report/human/004647/WC500249649.pdf 14. EMA. EPAR– Public assessment report for Rubraca®. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pu-blic_ assessment_report/human/004272/WC500249808.pdf 15. EMA.CHMP. Summary of positive opinion of Rubraca®. http://www.ema.eu-ropa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_autho-risation/ human/004272/WC500246362.pdf 16. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mu-tation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016 Mar 29;114(7):723-30. 17. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucapa-rib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label,phase 2 trial. Lancet Oncol. 2017 Jan;18(1):75-87 18. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A et al. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949- 1961. 19. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, 20. et al. Antitumor activity and safety of the PARP inhibitor rucaparib in pa-tients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 Nov;147(2):267-275. 21. Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA 22. advanced ovarian cancer. Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 23. 10.2147/DDDT.S130809. eCollection 2018. Review. 24. Minkowitz HS, Leiman D, Melson T, Singla N, DiDonato KP, Palmer PP. Sufen-tanil sublinigual tablet 30 mcg for the management of pain following abdominal surgery: a randomized, placebo-controlled, phase-3 study. Pain Pract 2017; 17 (7): 848-58. doi: 10.1111/papr.12531. Epub 2017 Feb 10. 25. Jove M, Griffin DW, Minkowitz HS, Ben-David B, Evashenk MA, Palmer PP. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized, placebo-controlled study. Anesthe-siology 2015; 123 (2): 434-43. 26. Minkowitz HS, Singla NK, Evashenk MA, Hwang SS, Chiang YK, Hamel LG et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. Reg Anesth Pain Med 2013; 38 (2): 131-9. 27. EMA. EPAR– Public assessment report for Kanjinti®. Disponible en: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_as-sessment_ report/human/004361/WC500249709.pdf
Revista-Sanidad-Militar-74-3
To see the actual publication please follow the link above